WELCOME TO
LSL PHARMA GROUP
People's health is at the heart of our mission!
PRESIDENT'S MESSAGE
“LSL Pharma Group Inc. comes from a long-term vision, a desire for expansion driven by the determination to further develop our expertise and thus offer a diversified range of life science products to our customers. The company's listing on the Toronto Venture Exchange (TSXV) represents one more step towards achieving this. Our five manufacturing plants of pharmaceutical products and natural health products (Steri-Med Pharma Inc., LSL Laboratory Inc., Virage Santé Inc. , Dermolab Pharma Ltd. and Laboratoire Du-Var Inc.) and our latest acquisition, LSL MedPlus Inc. (formerly Juno OTC), are constantly evolving to enable us to achieve our growth objectives. »
OUR SUBSIDIARIES
Your CDMO partner! LSL Laboratory has been developing and manufacturing natural health products for over
20 years.
Steri-Med manufactures sterile pharmaceutical products in the form of ointments for the whole family, even our four-legged friends.c
Founded in 1994, Virage Santé manufactures and distributes its own brands of natural
health products and is also a CDMO partner.
Dermolab Pharma specializes in the formulation and manufacturing of natural health, pharmaceutical and cosmetic products since 1985.
Since 1947,
Laboratoire Du-Var has specialized in the development and manufacture of cosmetics, natural health, and personal care products.
LSL MedPlus (formerly Juno OTC)
is specialized in private-label commercialization for major Canadian retail chains.
HEADLINE!
RESEARCH CAPITAL INITIATES ANALYST COVERAGE OF LSL PHARMA GROUP
Research Capital is the first independent equity research group to publish an analyst coverage report on LSL Pharma. Research Capital's initial report on LSL Pharma was authored by Andre Uddin, Ph.D.
LSL Pharma does not distribute analyst reports to persons outside of the Corporation. Please contact a Research Capital Corp investment advisor directly to obtain a copy of the report.
INVESTOR RELATIONS
